Abstract
Summary: Farge and colleagues describe a novel in vivo approach to identify and study primary acute myeloid leukemia (AML) cells that persist in the marrow after chemotherapy. They discovered that AML cells that persist in the mouse marrow after treatment with cytarabine have increased oxidative phosphorylation and that inhibiting oxidative phosphorylation can restore sensitivity to cytarabine. Cancer Discov; 7(7); 670–2. ©2017 AACR.
See related article by Farge et al., p. 716.
- ©2017 American Association for Cancer Research.
July 2017
Volume 7, Issue 7
Volume 7, Issue 7
Novel Mitochondrial Mechanisms of Cytarabine Resistance in Primary AML Cells
Jump to section
Advertisement